Semaglutide 2.4 mg weekly was superior to placebo for physical functioning across the four 68-week STEP 1-4 trials. PICO summary and expert commentary.
Browsing: GLP-1 Receptor Agonists
Clinical trial summaries for GLP-1 receptor agonists, including cardiovascular outcomes, glycaemic control, obesity, kidney outcomes, tolerability, and practice implications.
A prespecified analysis of the SELECT trial reports semaglutide produced a mean weight reduction of 10.2 percent versus 1.5 percent for placebo, sustained over four years in adults with cardiovascular disease and obesity but without diabetes. PICO summary and expert commentary.
A pre-specified secondary analysis of the SELECT trial found that once-weekly semaglutide 2.4 mg modestly reduced a composite kidney endpoint versus placebo in adults with overweight or obesity and established cardiovascular disease, without diabetes. PICO summary and expert commentary.
Prespecified pooled analysis of the STEP-HFpEF program shows once-weekly semaglutide 2.4 mg improved NYHA functional class versus placebo in obesity-related HFpEF. PICO summary and expert commentary.
In the FLOW randomised controlled trial, weekly semaglutide reduced major kidney disease events and cardiovascular death in patients with type 2 diabetes and chronic kidney disease. PICO summary and expert commentary.
A post hoc analysis testing whether machine-learning digital pathology reproduces pathologist scoring of liver biopsies in a phase II semaglutide NASH trial. PICO summary and expert commentary.
A phase 1 trial characterising oral semaglutide pharmacokinetics, pharmacodynamics and tolerability in 32 healthy Chinese adults. PICO summary and expert commentary.
A prespecified pooled analysis of the STEP-HFpEF and STEP-HFpEF DM trials showing that once-weekly semaglutide 2.4 mg improved NYHA functional class versus placebo in obesity-related HFpEF. PICO summary and expert commentary.
A published study protocol for a 52-week double-blind randomised trial of semaglutide plus empagliflozin versus each drug alone for NAFLD in type 2 diabetes. No efficacy results are reported yet. PICO summary and expert commentary.
A phase 2b trial of the GLP-1/glucagon receptor agonist cotadutide showed dose-dependent reductions in albuminuria in type 2 diabetes with CKD. PICO summary and expert commentary.